EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 689 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations January 18, 2021 ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical... October 8, 2025 Can Cooking With Nonstick Cookware Increase Your Cancer Risk? May 16, 2023 A Combination of Trastuzumab with Gemcitabine and Cisplatin Shows Promising Activity... November 24, 2023 Load more HOT NEWS FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive Stage Small Cell... Woman Helps Students With Special Needs Achieve Success After Graduation How Being an Athlete Prepared Me for My Cancer Experience How Becky is helping her children to keep their dad’s memory...
